A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Trial Profile

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 21 Nov 2017 According to a Novo Nordisk media release, based on the data from this trial, Health Canada has approved Victoza to reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes mellitus and established CVD when added to diet, exercise, and the current standard of care therapy.
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Sep 2017 Results of a state-transition analysis assessing effect of liraglutide addition, to standard of care, on clinical and economic outcomes over 25 years from a Canadian perspective presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top